Impact of Help-Seeking Behaviors on Allergic Rhinitis and Mental Health: A Longitudinal Study

February 9, 2026 updated by: QHSLab, Inc.

Impact of Help-Seeking Behaviors on Allergic Rhinitis, Asthma Control, and Mental Health: A Retrospective and Longitudinal Analysis of Allergy Medication Use

This study explores how help-seeking behaviors for both emotional well-being and allergies impact the management of allergic rhinitis, asthma, and mental health symptoms, including anxiety and depression. The research involves a retrospective and longitudinal analysis of patients who sought treatment for allergic rhinitis and mental health concerns. The goal is to highlight the importance of integrating mental health care into allergy treatment plans to improve overall patient outcomes.

Study Overview

Status

Recruiting

Conditions

Detailed Description

This study aims to investigate the impact of help-seeking behaviors (HSB) on allergic rhinitis (AR), asthma control, and mental health outcomes, such as anxiety and depression, using both retrospective and longitudinal data. The study examines patients who have been diagnosed with AR and mental health conditions to assess how seeking professional help for allergies, emotional well-being, or both influences symptom control and quality of life.

The research analyzes data from a diverse patient population to evaluate the effects of AR medications (intranasal steroids, antihistamines, decongestants, and leukotriene blockers) on both AR and mental health symptoms. Additionally, it explores the role of help-seeking behaviors in improving symptom management, specifically through the use of validated tools like the SNOT-22 for AR and the PHQ-GAD16 for mental health.

The study emphasizes the importance of integrating mental health screening and support into the treatment of allergic rhinitis and asthma. By analyzing real-world data, the research seeks to provide insights into how coordinated care approaches can enhance patient outcomes and inform future clinical practices.

Study Type

Observational

Enrollment (Estimated)

200000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • United States
    • Florida
      • West Palm Beach, Florida, United States, 33407
        • Recruiting
        • QHSLab
        • Contact:
        • Contact:
        • Principal Investigator:
          • Marcos A Sanchez-Gonzalez, MD, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

This repository collects data from primary care patients diagnosed with allergic rhinitis, asthma, anxiety, or depression. The repository aims to track health outcomes, medication usage, and help-seeking behaviors to support future research on the interaction between chronic physical and mental health conditions. The population includes adult patients who consent to the inclusion of their data and who seek care in a primary care setting for the specified conditions.

Description

Inclusion Criteria:

Adults (aged 18 years or older) Patients actively receiving care in a primary care setting. Patients who have provided informed consent for their health data to be included in the research repository.

Exclusion Criteria:

Patients who have not provided informed consent for their health data to be included in the research repository.

Patients diagnosed with chronic conditions outside the scope of allergic rhinitis, asthma, or mental health conditions (anxiety, depression).

Patients with severe mental health disorders or comorbidities that are unrelated to the conditions of interest (e.g., schizophrenia, bipolar disorder, etc.).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Allergic Rhinitis Symptom Severity (SNOT-22 Score)
Time Frame: baseline and yearly follow-up for up to 5 years
This outcome measures the long-term change in allergic rhinitis symptom severity over several years using the Sinonasal Outcome Test (SNOT-22). The SNOT-22 is a validated tool that assesses the impact of sinonasal conditions on quality of life. The study will track the effects of help-seeking behaviors for both allergies and mental health (anxiety and depression) on allergic rhinitis symptom control, examining changes in SNOT-22 scores over multiple follow-up periods. Scores range from 0 to 110, with higher scores indicating worse symptoms and lower quality of life.
baseline and yearly follow-up for up to 5 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Depression Symptoms (PHQ-9 Score)
Time Frame: Baseline and yearly follow-up for up to 5 years
This outcome measures the change in depressive symptoms using the Patient Health Questionnaire (PHQ-9). The PHQ-9 is a validated tool to assess the severity of depression. Scores range from 0 to 27, with higher scores indicating more severe depressive symptoms. The study will assess how help-seeking behaviors for both allergies and mental health impact the severity of depressive symptoms over time.
Baseline and yearly follow-up for up to 5 years
Change in Anxiety Symptoms (GAD-7 Score)
Time Frame: Baseline and yearly follow-up for up to 5 years
This outcome measures the change in anxiety symptoms using the Generalized Anxiety Disorder Scale (GAD-7). The GAD-7 is a validated tool to assess the severity of anxiety. Scores range from 0 to 21, with higher scores indicating more severe anxiety symptoms. The study will assess how help-seeking behaviors for both allergies and mental health impact the severity of anxiety symptoms over time.
Baseline and yearly follow-up for up to 5 years

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Effect of Help-Seeking Behaviors on Symptom Control and Quality of Life
Time Frame: Baseline and yearly follow-up for up to 5 years
This outcome evaluates the effect of help-seeking behaviors (seeking help for emotional well-being, allergies, or both) on overall symptom control and quality of life. The study will explore the relationship between help-seeking behaviors and improvements in allergic rhinitis symptoms (SNOT-22) and mental health outcomes (PHQ-9, GAD-7). Scores from each scale will be analyzed separately to assess the impact of help-seeking behaviors on these specific health outcomes.
Baseline and yearly follow-up for up to 5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

QHSLab, Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2020

Primary Completion (Estimated)

January 25, 2027

Study Completion (Estimated)

January 25, 2027

Study Registration Dates

First Submitted

September 13, 2024

First Submitted That Met QC Criteria

September 30, 2024

First Posted (Actual)

October 2, 2024

Study Record Updates

Last Update Posted (Actual)

February 11, 2026

Last Update Submitted That Met QC Criteria

February 9, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • QHSLab 001-2024

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data (IPD) will not be shared due to privacy concerns and the need to protect patient confidentiality. Data collected in this study is used for internal analysis, and only aggregated, anonymized data will be made available for research purposes. This ensures compliance with privacy regulations such as HIPAA and protects patient identities.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Allergic

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe